Explore

Trendline Trendline
Sensei Biotherapeutics Advances Cancer Treatment with PIKTOR Amid Financial Growth

Sensei Biotherapeutics Advances Cancer Treatment with PIKTOR Amid Financial Growth

Sensei Biotherapeutics Advances Cancer Treatment with PIKTOR Amid Financial Growth
Trendline Trendline
Marker Therapeutics Reports Improved Financials Amidst Ongoing Clinical Developments

Marker Therapeutics Reports Improved Financials Amidst Ongoing Clinical Developments

Marker Therapeutics Reports Improved Financials Amidst Ongoing Clinical Developments
Trendline Trendline
Citius Oncology Secures $36.5 Million Financing Amid Strong LYMPHIR Launch

Citius Oncology Secures $36.5 Million Financing Amid Strong LYMPHIR Launch

Citius Oncology Secures $36.5 Million Financing Amid Strong LYMPHIR Launch
Trendline Trendline
Citius Oncology Reports Q2 2026 Financial Results Highlighting LYMPHIR Launch Success

Citius Oncology Reports Q2 2026 Financial Results Highlighting LYMPHIR Launch Success

Citius Oncology Reports Q2 2026 Financial Results Highlighting LYMPHIR Launch Success
Trendline Trendline
Enveric Biosciences Reports Q1 2026 Financial Results and Advances Lead Drug Candidate

Enveric Biosciences Reports Q1 2026 Financial Results and Advances Lead Drug Candidate

Enveric Biosciences Reports Q1 2026 Financial Results and Advances Lead Drug Candidate
Trendline Trendline
Bronstein, Gewirtz Grossman, LLC Files Class Action Lawsuit Against Immutep Limited for Securities Violations

Bronstein, Gewirtz Grossman, LLC Files Class Action Lawsuit Against Immutep Limited for Securities Violations

Bronstein, Gewirtz Grossman, LLC Files Class Action Lawsuit Against Immutep Limited for Securities Violations
Trendline Trendline
Northwest Biotherapeutics Reports Q1 2026 Financial Results with Revenue Increase

Northwest Biotherapeutics Reports Q1 2026 Financial Results with Revenue Increase

Northwest Biotherapeutics Reports Q1 2026 Financial Results with Revenue Increase
Trendline Trendline
Inhibrx Biosciences Reports Financial Results Amid Ongoing Clinical Trials

Inhibrx Biosciences Reports Financial Results Amid Ongoing Clinical Trials

Inhibrx Biosciences Reports Financial Results Amid Ongoing Clinical Trials
Trendline Trendline
Citius Oncology Reports Strong Financial Growth and Strategic Developments in Q2 2026

Citius Oncology Reports Strong Financial Growth and Strategic Developments in Q2 2026

Citius Oncology Reports Strong Financial Growth and Strategic Developments in Q2 2026
Trendline Trendline
Nanoviricides Reports Third Quarter Loss Amid Clinical Advancements

Nanoviricides Reports Third Quarter Loss Amid Clinical Advancements

Nanoviricides Reports Third Quarter Loss Amid Clinical Advancements
Trendline Trendline
Brainstorm Cell Therapeutics Reports Narrowed Loss in Q1 2026 Amid Clinical Developments

Brainstorm Cell Therapeutics Reports Narrowed Loss in Q1 2026 Amid Clinical Developments

Brainstorm Cell Therapeutics Reports Narrowed Loss in Q1 2026 Amid Clinical Developments
Trendline Trendline
Marker Therapeutics Reports Q1 2026 Financial Results with Reduced Net Loss

Marker Therapeutics Reports Q1 2026 Financial Results with Reduced Net Loss

Marker Therapeutics Reports Q1 2026 Financial Results with Reduced Net Loss